PL4182311T3 - Pochodne 1-metylo-1h-pirazol-3-ilu do zastosowania w leczeniu chorób neowaskularnych - Google Patents
Pochodne 1-metylo-1h-pirazol-3-ilu do zastosowania w leczeniu chorób neowaskularnychInfo
- Publication number
- PL4182311T3 PL4182311T3 PL21748927.7T PL21748927T PL4182311T3 PL 4182311 T3 PL4182311 T3 PL 4182311T3 PL 21748927 T PL21748927 T PL 21748927T PL 4182311 T3 PL4182311 T3 PL 4182311T3
- Authority
- PL
- Poland
- Prior art keywords
- pyrazol
- derivatives
- methyl
- treatment
- neovascular diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2010829.6A GB202010829D0 (en) | 2020-07-14 | 2020-07-14 | Compounds for treatment of neovascular diseases |
| PCT/GB2021/051810 WO2022013555A1 (en) | 2020-07-14 | 2021-07-14 | 1-methyl-1h-pyrazol-3-yl derivatives for use in the treatment of neovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4182311T3 true PL4182311T3 (pl) | 2025-11-12 |
Family
ID=72139988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21748927.7T PL4182311T3 (pl) | 2020-07-14 | 2021-07-14 | Pochodne 1-metylo-1h-pirazol-3-ilu do zastosowania w leczeniu chorób neowaskularnych |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US12024504B2 (pl) |
| EP (1) | EP4182311B1 (pl) |
| JP (1) | JP2023535157A (pl) |
| KR (1) | KR20230052890A (pl) |
| CN (1) | CN116075506B (pl) |
| AU (1) | AU2021309894A1 (pl) |
| BR (1) | BR112023000571A2 (pl) |
| CA (1) | CA3183466A1 (pl) |
| DK (1) | DK4182311T3 (pl) |
| ES (1) | ES3039003T3 (pl) |
| FI (1) | FI4182311T3 (pl) |
| GB (1) | GB202010829D0 (pl) |
| HR (1) | HRP20250955T1 (pl) |
| HU (1) | HUE072558T2 (pl) |
| LT (1) | LT4182311T (pl) |
| MX (1) | MX2023000570A (pl) |
| PL (1) | PL4182311T3 (pl) |
| PT (1) | PT4182311T (pl) |
| RS (1) | RS67158B1 (pl) |
| SI (1) | SI4182311T1 (pl) |
| SM (1) | SMT202500307T1 (pl) |
| WO (1) | WO2022013555A1 (pl) |
| ZA (1) | ZA202301105B (pl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202010829D0 (en) * | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
| WO2024155864A1 (en) * | 2023-01-20 | 2024-07-25 | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. | Sprk1 inhibitors and methods of use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE462006T1 (de) | 2001-08-01 | 2010-04-15 | Univ Bristol | Isoform des vegfs |
| EP1712242B1 (en) | 2003-12-26 | 2018-05-30 | Masatoshi Hagiwara | Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient |
| CA2649043C (en) * | 2006-04-19 | 2013-09-17 | Astellas Pharma Inc. | Azolecarboxamide derivative |
| GB0704678D0 (en) | 2007-03-09 | 2007-04-18 | Univ Bristol | Pro- and anti-angiogenic treatments |
| GB0803912D0 (en) | 2008-02-29 | 2008-05-07 | Univ Bristol | Novel Uses of VEGFxxxb |
| EP2358382A2 (en) | 2008-11-22 | 2011-08-24 | The University of Bristol | NOVEL USES OF VEGFxxxB |
| GB201009173D0 (en) | 2010-05-28 | 2010-07-14 | Univ Bristol | Treatment of pain |
| JP2016504270A (ja) * | 2012-10-17 | 2016-02-12 | ザ ユニバーシティ オブ ブリストル | 眼血管形成（ｏｃｕｌａｒｎｅｏｖａｓｃｕｌａｎ）を治療するのに有用な化合物 |
| GB201406956D0 (en) | 2014-04-17 | 2014-06-04 | Univ Nottingham | Compounds |
| GB201518365D0 (en) * | 2015-10-16 | 2015-12-02 | Exonate Ltd | Compounds |
| JOP20170147B1 (ar) * | 2016-07-07 | 2021-08-17 | Salvat Lab Sa | تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة |
| JP7261793B2 (ja) | 2017-09-27 | 2023-04-20 | エクソネイト リミテッド | Ｓｒｐｋ１阻害剤 |
| CN110710099B (zh) | 2017-09-29 | 2024-02-02 | 株式会社日立产机系统 | 数据获取方法、逆变器和旋转电机 |
| GB202010829D0 (en) * | 2020-07-14 | 2020-08-26 | Exonate Ltd | Compounds for treatment of neovascular diseases |
-
2020
- 2020-07-14 GB GBGB2010829.6A patent/GB202010829D0/en not_active Ceased
-
2021
- 2021-07-14 PT PT217489277T patent/PT4182311T/pt unknown
- 2021-07-14 JP JP2023502982A patent/JP2023535157A/ja active Pending
- 2021-07-14 KR KR1020237005137A patent/KR20230052890A/ko active Pending
- 2021-07-14 PL PL21748927.7T patent/PL4182311T3/pl unknown
- 2021-07-14 HU HUE21748927A patent/HUE072558T2/hu unknown
- 2021-07-14 FI FIEP21748927.7T patent/FI4182311T3/fi active
- 2021-07-14 ES ES21748927T patent/ES3039003T3/es active Active
- 2021-07-14 EP EP21748927.7A patent/EP4182311B1/en active Active
- 2021-07-14 DK DK21748927.7T patent/DK4182311T3/da active
- 2021-07-14 WO PCT/GB2021/051810 patent/WO2022013555A1/en not_active Ceased
- 2021-07-14 HR HRP20250955TT patent/HRP20250955T1/hr unknown
- 2021-07-14 CA CA3183466A patent/CA3183466A1/en active Pending
- 2021-07-14 LT LTEPPCT/GB2021/051810T patent/LT4182311T/lt unknown
- 2021-07-14 BR BR112023000571A patent/BR112023000571A2/pt unknown
- 2021-07-14 RS RS20250853A patent/RS67158B1/sr unknown
- 2021-07-14 MX MX2023000570A patent/MX2023000570A/es unknown
- 2021-07-14 SI SI202130341T patent/SI4182311T1/sl unknown
- 2021-07-14 SM SM20250307T patent/SMT202500307T1/it unknown
- 2021-07-14 CN CN202180049067.2A patent/CN116075506B/zh active Active
- 2021-07-14 AU AU2021309894A patent/AU2021309894A1/en active Pending
-
2022
- 2022-08-03 US US17/817,136 patent/US12024504B2/en active Active
-
2023
- 2023-01-26 ZA ZA2023/01105A patent/ZA202301105B/en unknown
-
2024
- 2024-03-13 US US18/603,489 patent/US20240300929A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240300929A1 (en) | 2024-09-12 |
| MX2023000570A (es) | 2023-04-19 |
| ES3039003T3 (en) | 2025-10-16 |
| HRP20250955T1 (hr) | 2025-10-10 |
| CN116075506A (zh) | 2023-05-05 |
| LT4182311T (lt) | 2025-09-25 |
| PT4182311T (pt) | 2025-08-27 |
| US20220411412A1 (en) | 2022-12-29 |
| GB202010829D0 (en) | 2020-08-26 |
| WO2022013555A1 (en) | 2022-01-20 |
| SI4182311T1 (sl) | 2025-11-28 |
| KR20230052890A (ko) | 2023-04-20 |
| RS67158B1 (sr) | 2025-09-30 |
| EP4182311A1 (en) | 2023-05-24 |
| ZA202301105B (en) | 2025-07-30 |
| DK4182311T3 (da) | 2025-08-25 |
| US12024504B2 (en) | 2024-07-02 |
| JP2023535157A (ja) | 2023-08-16 |
| SMT202500307T1 (it) | 2025-11-10 |
| CN116075506B (zh) | 2025-10-10 |
| FI4182311T3 (fi) | 2025-08-22 |
| EP4182311B1 (en) | 2025-06-04 |
| CA3183466A1 (en) | 2022-01-20 |
| HUE072558T2 (hu) | 2025-11-28 |
| AU2021309894A1 (en) | 2023-03-09 |
| BR112023000571A2 (pt) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285269A (en) | Compositions and methods for treating neurocognitive disorders | |
| HUE063145T2 (hu) | Deuterált vegyületek rákos megbetegedések kezelésében történõ alkalmazásra | |
| IL285270A (en) | Compositions and methods for treating neurocognitive disorders | |
| HUE058931T2 (hu) | Pilokarpin hidroklorid alkalmazása presbyopia kezelésére | |
| IL287957A (en) | Methods of using anti-cd79b immunoconjugates to treat follicular lymphoma | |
| IL285708A (en) | Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders | |
| IL287796A (en) | Compositions and methods for the treatment of atpase-mediated diseases | |
| CL2018002807A1 (es) | Métodos de tratamiento de cánceres pediátricos. | |
| HUE060322T2 (hu) | Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra | |
| PL3972643T3 (pl) | Antagoniści układu dopełniacza do stosowania w sposobach leczenia neuropatii paraproteinemicznych | |
| EP3347010A4 (en) | SYNTHESIS AND COMPOSITION OF PHOTODYNAMIC THERAPEUTIC AGENTS FOR THE TARGETED TREATMENT OF CANCER | |
| HUE058151T2 (hu) | Enterococcusból származó flagellin készítményei terápiában történõ alkalmazásra | |
| IL281244A (en) | Combination therapy for the treatment of liver disease | |
| MA46608A (fr) | Formulation liposomale destinée à être utilisée dans le traitement du cancer | |
| IL287704A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| IL290891A (en) | Compositions and methods of treating vascular diseases | |
| IL311638A (en) | Compositions and methods for treating cag repeat diseases | |
| MA47111A (fr) | Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer | |
| EP4203928A4 (en) | Inhalable therapeutic agents | |
| IL292186A (en) | Compositions and methods for treating blood disorders | |
| PL4182311T3 (pl) | Pochodne 1-metylo-1h-pirazol-3-ilu do zastosowania w leczeniu chorób neowaskularnych | |
| IL248468A0 (en) | Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing | |
| IL285268A (en) | Compositions and methods for treating neurocognitive disorders | |
| IL272194A (en) | Multispecific antibodies for use in treating diseases | |
| IL259710A (en) | Compositions and methods of treatment for mvid and related diseases |